Validering av ny avancerad DNA-diagnostik för förenklad och kostnadseffektiv analys av genetiska sjukdomar

Diarienummer 2014-03321
Koordinator VANADIS DIAGNOSTICS AB
Bidrag från Vinnova 3 615 363 kronor
Projektets löptid november 2014 - maj 2016
Status Avslutat

Syfte och mål

The goal of the project was to support development of Vanadis smart NIPT technology, from early stage concept to clinical validation. We have successfully proven the technology on clinical samples, collected by our partner at Karolinska Hospital (behovsägaren), and the manual assay has been implemented on prototype instruments.

Resultat och förväntade effekter

As a result of the successful project, PerkinElmer acquired Vanadis in December 2015. PerkinElmer is a US corporation that is the market leader in traditional prenatal diagnosis. Vanadis will now have financial back up to take the technology to commercial stage, including filing for CE-IVD.

Upplägg och genomförande

The project was focused on the work packages described in the application. The company was staffed accordingly and individual project plans for the individual WPs was generated. The main goal with the company remained intact thoughout the project, keeping the team focused on the execution.

Externa länkar

Vanadis Diagnostics home page

Texten på denna sida har projektgruppen själv formulerat och innehållet är ej granskat av våra redaktörer. Projektets koordinator kan ge dig mer information.